Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 7Leukemia, Myeloid, Acute 6Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Sezary Syndrome 2Sarcoma, Myeloid 2Recurrence 2Mycosis Fungoides 2Lymphoma, Non-Hodgkin 2Lymphoma 2Lung Neoplasms 2Colonic Neoplasms 2Carcinoma, Hepatocellular 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Clear Cell 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Cancer Metastatic 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1

Interventions

Gemcitabine 60Cisplatin 38Oxaliplatin 30Capecitabine 28Fluorouracil 21Leucovorin 19pembrolizumab 11Irinotecan 11durvalumab 9130-nm albumin-bound paclitaxel 9Erlotinib Hydrochloride 8Trastuzumab 7Bevacizumab 7Platinum 6Magnetic Resonance Spectroscopy 6Albumin-Bound Paclitaxel 61,2-diaminocyclohexaneplatinum II citrate 6Taxes 5Specimen Handling 5Sorafenib 5Radiotherapy 5Carboplatin 5Docetaxel 4Biopsy 4trifluridine tipiracil drug combination 3dehydroftorafur 3atezolizumab 3Paclitaxel 3Lapatinib 3Interleukin-12 Subunit p35 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Gallbladder Neoplasms × devimistat × Clear all
NCT04203160 2025-12-31

Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

University of Michigan Rogel Cancer Center

Phase 1/2 Terminated
75 enrolled 17 charts
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡